Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

Robert O. Bonow; Robert A. Harrington; Clyde W. Yancy

doi:10.1001/jamacardio.2017.3656

Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

Robert O. Bonow^*, Robert A. Harrington, Clyde W. Yancy

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Editorial › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	1298-1299
Number of pages	2
Journal	JAMA cardiology
Volume	2
Issue number	12
DOIs	https://doi.org/10.1001/jamacardio.2017.3656
State	Published - Dec 2017

Funding

completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2017.3656

Cite this

@article{25ad5c9c3c4d4c4aa6c30f7c07e6f0f5,

title = "Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling",

author = "Bonow, {Robert O.} and Harrington, {Robert A.} and Yancy, {Clyde W.}",

note = "Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.",

year = "2017",

month = dec,

doi = "10.1001/jamacardio.2017.3656",

language = "English (US)",

volume = "2",

pages = "1298--1299",

journal = "JAMA cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "12",

}

TY - JOUR

T1 - Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

AU - Bonow, Robert O.

AU - Harrington, Robert A.

AU - Yancy, Clyde W.

N1 - Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.

PY - 2017/12

Y1 - 2017/12

UR - http://www.scopus.com/inward/record.url?scp=85040001292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040001292&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2017.3656

DO - 10.1001/jamacardio.2017.3656

M3 - Editorial

C2 - 29049827

AN - SCOPUS:85040001292

SN - 2380-6583

VL - 2

SP - 1298

EP - 1299

JO - JAMA cardiology

JF - JAMA cardiology

IS - 12

ER -

Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this